Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States
**Background:** Gastroesophageal reflux disease (GERD) is a risk factor for Barrett’s esophagus (BE) and BE-related neoplasia (BERN). **Objectives:** This study aimed to evaluate healthcare resource utilization (HRU) and costs associated with GERD, BE, and BERN in the United States. **Methods:** Adu...
Saved in:
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2023-03-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/001c.68191 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1823860358604914688 |
---|---|
author | Prateek Sharma Gary W. Falk Menaka Bhor A. Burak Ozbay Dominick Latremouille-Viau Annie Guerin Sherry Shi Margaret M. Elvekrog Paul Limburg |
author_facet | Prateek Sharma Gary W. Falk Menaka Bhor A. Burak Ozbay Dominick Latremouille-Viau Annie Guerin Sherry Shi Margaret M. Elvekrog Paul Limburg |
author_sort | Prateek Sharma |
collection | DOAJ |
description | **Background:** Gastroesophageal reflux disease (GERD) is a risk factor for Barrett’s esophagus (BE) and BE-related neoplasia (BERN).
**Objectives:** This study aimed to evaluate healthcare resource utilization (HRU) and costs associated with GERD, BE, and BERN in the United States.
**Methods:** Adult patients with GERD, nondysplastic BE (NDBE), and BERN (including indefinite for dysplasia \[IND\], low-grade dysplasia \[LGD\], high-grade dysplasia \[HGD\] or esophageal adenocarcinoma \[EAC\]), were identified from a large US administrative claims database, the IBM Truven Health MarketScan® databases (Q1/2015-Q4/2019). Patients were categorized into the corresponding mutually exclusive EAC-risk/diagnosis cohorts based on the most advanced stage from GERD to EAC using diagnosis codes in medical claims. Disease-related HRU and costs (2020 USD) were calculated for each cohort.
**Results:** Patients were categorized into the following EAC-risk/diagnosis cohorts: 3 310 385 into GERD, 172 481 into NDBE, 11 516 into IND, 4332 into LGD, 1549 into HGD, and 11 676 into EAC. Disease-related annual mean number of inpatient admissions, office visits, and emergency department visits by cohort were 0.09, 1.45, and 0.19 for GERD; 0.08, 1.55, and 0.10 for NDBE; 0.10, 1.92, and 0.13 for IND; 0.09, 2.05, and 0.10 for LGD; 0.12, 2.16, and 0.14 for HGD; and 1.43, 6.27, and 0.87 for EAC. Disease-related annual mean total healthcare costs by cohort were $6955 for GERD, $8755 for NDBE, $9675 for IND, $12 241 for LGD, $24 239 for HGD, and $146 319 for EAC.
**Discussion:** Patients with GERD, BE, and BERN had important HRU and costs, including inpatient admissions and office visits. As patients progressed to more advanced stages, there was substantially higher disease-related resource utilization, with associated costs being 16 times higher in patients with EAC than those with NDBE.
**Conclusions:** Findings suggest the need for early identification of high-risk individuals prior to progression to EAC to potentially improve clinical and economic outcomes in this population. |
format | Article |
id | doaj-art-8f6873c3d63c4affbd3f961ddbcfe609 |
institution | Kabale University |
issn | 2327-2236 |
language | English |
publishDate | 2023-03-01 |
publisher | Columbia Data Analytics, LLC |
record_format | Article |
series | Journal of Health Economics and Outcomes Research |
spelling | doaj-art-8f6873c3d63c4affbd3f961ddbcfe6092025-02-10T16:12:50ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362023-03-01101Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United StatesPrateek SharmaGary W. FalkMenaka BhorA. Burak OzbayDominick Latremouille-ViauAnnie GuerinSherry ShiMargaret M. ElvekrogPaul Limburg**Background:** Gastroesophageal reflux disease (GERD) is a risk factor for Barrett’s esophagus (BE) and BE-related neoplasia (BERN). **Objectives:** This study aimed to evaluate healthcare resource utilization (HRU) and costs associated with GERD, BE, and BERN in the United States. **Methods:** Adult patients with GERD, nondysplastic BE (NDBE), and BERN (including indefinite for dysplasia \[IND\], low-grade dysplasia \[LGD\], high-grade dysplasia \[HGD\] or esophageal adenocarcinoma \[EAC\]), were identified from a large US administrative claims database, the IBM Truven Health MarketScan® databases (Q1/2015-Q4/2019). Patients were categorized into the corresponding mutually exclusive EAC-risk/diagnosis cohorts based on the most advanced stage from GERD to EAC using diagnosis codes in medical claims. Disease-related HRU and costs (2020 USD) were calculated for each cohort. **Results:** Patients were categorized into the following EAC-risk/diagnosis cohorts: 3 310 385 into GERD, 172 481 into NDBE, 11 516 into IND, 4332 into LGD, 1549 into HGD, and 11 676 into EAC. Disease-related annual mean number of inpatient admissions, office visits, and emergency department visits by cohort were 0.09, 1.45, and 0.19 for GERD; 0.08, 1.55, and 0.10 for NDBE; 0.10, 1.92, and 0.13 for IND; 0.09, 2.05, and 0.10 for LGD; 0.12, 2.16, and 0.14 for HGD; and 1.43, 6.27, and 0.87 for EAC. Disease-related annual mean total healthcare costs by cohort were $6955 for GERD, $8755 for NDBE, $9675 for IND, $12 241 for LGD, $24 239 for HGD, and $146 319 for EAC. **Discussion:** Patients with GERD, BE, and BERN had important HRU and costs, including inpatient admissions and office visits. As patients progressed to more advanced stages, there was substantially higher disease-related resource utilization, with associated costs being 16 times higher in patients with EAC than those with NDBE. **Conclusions:** Findings suggest the need for early identification of high-risk individuals prior to progression to EAC to potentially improve clinical and economic outcomes in this population.https://doi.org/10.36469/001c.68191 |
spellingShingle | Prateek Sharma Gary W. Falk Menaka Bhor A. Burak Ozbay Dominick Latremouille-Viau Annie Guerin Sherry Shi Margaret M. Elvekrog Paul Limburg Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States Journal of Health Economics and Outcomes Research |
title | Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States |
title_full | Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States |
title_fullStr | Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States |
title_full_unstemmed | Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States |
title_short | Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States |
title_sort | healthcare resource utilization and costs among patients with gastroesophageal reflux disease barrett s esophagus and barrett s esophagus related neoplasia in the united states |
url | https://doi.org/10.36469/001c.68191 |
work_keys_str_mv | AT prateeksharma healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates AT garywfalk healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates AT menakabhor healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates AT aburakozbay healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates AT dominicklatremouilleviau healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates AT annieguerin healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates AT sherryshi healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates AT margaretmelvekrog healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates AT paullimburg healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates |